Citadel Securities Maintains an 'Edge Negative' on Celgene (CELG); Behind the Smoke and Mirrors: Revlimid Ex-U.S. Growth Updated Guidance Suggests Slowdown Ahead

Go back to Citadel Securities Maintains an 'Edge Negative' on Celgene (CELG); Behind the Smoke and Mirrors: Revlimid Ex-U.S. Growth Updated Guidance Suggests Slowdown Ahead